Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that is highly aggressive with a poor prognosis. There is no standard treatment for BPDCN. Although conventional chemotherapies are usually sensitive in the initial therapy, relapse and drug resistance are inevitable within a short duration. Targeted therapies have enlightened new prospects for the treatment of BPDCN, especially for those in a frail state and intolerable to standard chemotherapies or hematopoietic stem cell transplantation. Here, we report an 82-year-old man diagnosed with cutaneous-limited BPDCN. Considering the old age and limited involvement of the tumor, we reduced the dosage of venetoclax. His skin lesions subsided significantly after 1 cycle of azacytidine (100 mg d1-7) combined with reduced doses of venetoclax (200 mg d1-14). The reduction in the dose of venetoclax avoided severe myelosuppression while achieving satisfactory outcomes. The patient received 2 cycles of therapy with no skin lesions re-occurred for 7 months before relapsing..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
---|---|
Enthalten in: |
Annals of hematology - 103(2024), 3 vom: 29. Jan., Seite 999-1005 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Qiuyan [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Azacitidine |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s00277-024-05633-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR054763592 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR054763592 | ||
003 | DE-627 | ||
005 | 20240215064636.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240215s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00277-024-05633-y |2 doi | |
035 | |a (DE-627)SPR054763592 | ||
035 | |a (SPR)s00277-024-05633-y-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Qiuyan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that is highly aggressive with a poor prognosis. There is no standard treatment for BPDCN. Although conventional chemotherapies are usually sensitive in the initial therapy, relapse and drug resistance are inevitable within a short duration. Targeted therapies have enlightened new prospects for the treatment of BPDCN, especially for those in a frail state and intolerable to standard chemotherapies or hematopoietic stem cell transplantation. Here, we report an 82-year-old man diagnosed with cutaneous-limited BPDCN. Considering the old age and limited involvement of the tumor, we reduced the dosage of venetoclax. His skin lesions subsided significantly after 1 cycle of azacytidine (100 mg d1-7) combined with reduced doses of venetoclax (200 mg d1-14). The reduction in the dose of venetoclax avoided severe myelosuppression while achieving satisfactory outcomes. The patient received 2 cycles of therapy with no skin lesions re-occurred for 7 months before relapsing. | ||
650 | 4 | |a Blastic plasmacytoid dendritic cell neoplasm |7 (dpeaa)DE-He213 | |
650 | 4 | |a Venetoclax |7 (dpeaa)DE-He213 | |
650 | 4 | |a Azacitidine |7 (dpeaa)DE-He213 | |
700 | 1 | |a Zhao, Yajing |4 aut | |
700 | 1 | |a Zang, Xiao |4 aut | |
700 | 1 | |a Zhou, Guizhi |4 aut | |
700 | 1 | |a Liu, Yongxia |4 aut | |
700 | 1 | |a Feng, Qi |4 aut | |
700 | 1 | |a Li, Xin |4 aut | |
700 | 1 | |a Wang, Wen |4 aut | |
700 | 1 | |a Dong, Xiaoyuan |4 aut | |
700 | 1 | |a Liu, Xinguang |4 aut | |
700 | 1 | |a Peng, Jun |4 aut | |
700 | 1 | |a Liu, Chuanfang |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1955 |g 103(2024), 3 vom: 29. Jan., Seite 999-1005 |w (DE-627)SPR003573435 |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
773 | 1 | 8 | |g volume:103 |g year:2024 |g number:3 |g day:29 |g month:01 |g pages:999-1005 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00277-024-05633-y |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 103 |j 2024 |e 3 |b 29 |c 01 |h 999-1005 |